UOC
VTYX

UBS O'Connor’s Ventyx Biosciences VTYX Stock Holding History

UBS O'Connor’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-79,000
Closed -$169K – 455
2025
Q2 		$169K Buy
+79,000
New +$128K ﹤0.01% 298
2025
Q1 		– Sell
-244,000
Closed -$534K – 471
2024
Q4 		$534K Buy
244,000
+44,000
+22% +$99.7K 0.01% 277
2024
Q3 		$436K Buy
+200,000
New +$460K 0.01% 350
2024
Q2 		– Sell
-134,000
Closed -$737K – 639
2024
Q1 		$737K Buy
+134,000
New +$613K 0.02% 304
2023
Q4 		– Sell
-45,463
Closed -$432K – 610
2023
Q3 		$1.58M Sell
45,463
-13,000
-22% -$449K 0.03% 271
2023
Q2 		$1.92M Buy
58,463
+11,437
+24% +$394K 0.04% 302
2023
Q1 		$1.58M Buy
47,026
+5,239
+13% +$204K 0.04% 363
2022
Q4 		$1.37M Buy
41,787
+12,387
+42% +$367K 0.03% 528
2022
Q3 		$1.03M Buy
+29,400
New +$651K 0.01% 745

Other funds holding VTYX

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS O'Connor's VTYX Position: Q3 2025 in Review

UBS O'Connor sold out of Ventyx Biosciences (VTYX) in Q3 2025, closing a stake of 79,000 shares — an estimated $169K sold.

UBS O'Connor first reported a position in VTYX in Q3 2022 and held it in 9 quarters. The position peaked at $1.92M in Q2 2023. 110 funds tracked by Wall St. Rank hold VTYX as of Q3 2025.

  • UBS O'Connor reported no remaining Ventyx Biosciences position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 79,000 Ventyx Biosciences shares in Q3 2025, an estimated $169K.
  • UBS O'Connor first reported a position in Ventyx Biosciences in Q3 2022 and held it in 9 quarters.
  • UBS O'Connor's Ventyx Biosciences position peaked at $1.92M in Q2 2023.
  • 110 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.